SCHEDULE: Wellington Management Boosts Crinetics Stake to 6.2%

Wellington Management Group and its affiliates have disclosed a 6.2% beneficial ownership stake in Crinetics Pharmaceuticals, Inc. common stock.

Summary

• Wellington Management Group LLP, along with its affiliates Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP, collectively reported beneficial ownership of 5,807,308 shares of Crinetics Pharmaceuticals, Inc. Common Stock.
• This aggregate ownership represents 6.2% of Crinetics Pharmaceuticals, Inc.'s outstanding common stock.
• The reporting entities hold shared voting power over 4,879,998 shares and shared dispositive power over 5,807,308 shares.
• The securities are owned of record by clients of the Wellington Investment Advisers, with no single client known to hold more than five percent of this class of securities.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as a significant institutional ownership stake by a major firm like Wellington Management can be interpreted as a positive signal of confidence in the company's long-term prospects, although the filing itself is purely factual and does not contain performance-related information.

Positives

• The disclosure of a significant institutional ownership stake by Wellington Management, a reputable investment firm, may be viewed as a vote of confidence in Crinetics Pharmaceuticals, Inc.

Negatives

• NA

Risks

• This Schedule 13G filing is a disclosure of beneficial ownership and does not contain information regarding specific risks related to Crinetics Pharmaceuticals, Inc.'s operations or financial performance.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Crinetics Pharmaceuticals, Inc.'s future outlook.

Industry Context

This filing indicates a significant institutional investment in Crinetics Pharmaceuticals, Inc., a company operating in the biotechnology and pharmaceutical sector. Such investments reflect investor interest in the company's potential within the broader industry, though this filing does not provide specific industry trend analysis.

Stakeholder Impact

• Shareholders may view the increased institutional ownership by Wellington Management as a positive indicator, potentially enhancing investor confidence and market stability for Crinetics Pharmaceuticals, Inc.

Key Dates

Keywords

Crinetics Pharmaceuticals, Wellington Management, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, CRNX, Pharmaceuticals, Biotechnology